A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to expand its ...
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
This article is authored by Dr YK Gupta, president, AIIMS, Jammu and Ankush Kapoor, founder & CEO, Pharma NXT Biotech.
US Food and Drug Administration (US FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) ...
Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...
Biocon added 1.34% to Rs 348.55 after the company's wholly owned subsidiary Biocon Pharma announced the receipt of U.S Food and Drug Administration (US FDA) approval for its ANDA Norepinephrine ...
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...
After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
The Chosun Ilbo on MSN4d
Korean biotech firms race into $26 billion U.S. biosimilar marketSouth Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...
The company's objective was to assess the essential documentation for submission, determine the necessity of conducting ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback